4 analysts have expressed a variety of opinions on NovoCure (NASDAQ:NVCR) over the past quarter, offering a diverse set of opinions from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $23.0, a high estimate of $28.00, and a low estimate of $20.00. This current average reflects an increase of 7.58% from the previous average price target of $21.38.

Investigating Analyst Ratings...